Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
Hervé Rubie, Julia Chisholm, Anne Sophie Defachelles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group RMS 2005 Trial
Gianni Bisogno, Julia Chisholm, Raquel Hladun, et al.
Cancer
|
May 26, 2018
Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego, Ilaria Zanetti, Daniel Orbach, et al.
Cancer
|
February 24, 2024
Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram
Gian Luca De Salvo, Paola Del Bianco, Veronique Minard-Colin, et al.
The Lancet. Oncology
|
September 29, 2019
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, et al.
Pediatric Radiology
|
August 14, 2025
Early radiologic tumour volume response in non-metastatic rhabdomyosarcoma is not predictive for survival
Isabelle S A de Vries, Carlo Morosi, Gianni Bisogno, et al.
The Lancet. Oncology
|
June 27, 2018
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno, Meriel Jenney, Christophe Bergeron, et al.
Head & Neck
|
November 15, 2024
Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study
Reineke A Schoot, Pieter Taselaar, Giovanni Scarzello, et al.
Cancer Medicine
|
September 2, 2020
Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study
Sheila E J Terwisscha van Scheltinga, Marc H W A Wijnen, Hélène Martelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
Hervé Rubie, Julia Chisholm, Anne Sophie Defachelles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group RMS 2005 Trial
Gianni Bisogno, Julia Chisholm, Raquel Hladun, et al.
Cancer
|
May 26, 2018
Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego, Ilaria Zanetti, Daniel Orbach, et al.
Cancer
|
February 24, 2024
Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram
Gian Luca De Salvo, Paola Del Bianco, Veronique Minard-Colin, et al.
The Lancet. Oncology
|
September 29, 2019
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, et al.
Pediatric Radiology
|
August 14, 2025
Early radiologic tumour volume response in non-metastatic rhabdomyosarcoma is not predictive for survival
Isabelle S A de Vries, Carlo Morosi, Gianni Bisogno, et al.
The Lancet. Oncology
|
June 27, 2018
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno, Meriel Jenney, Christophe Bergeron, et al.
Head & Neck
|
November 15, 2024
Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study
Reineke A Schoot, Pieter Taselaar, Giovanni Scarzello, et al.
Cancer Medicine
|
September 2, 2020
Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study
Sheila E J Terwisscha van Scheltinga, Marc H W A Wijnen, Hélène Martelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Page
of 5